New MS drug switch study aims to simplify treatment
NCT ID NCT04178005
First seen Jan 11, 2026 · Last updated Apr 27, 2026 · Updated 14 times
Summary
This study looks at whether people with relapsing-remitting or active secondary progressive multiple sclerosis can safely switch from natalizumab to cladribine tablets. The goal is to see if cladribine can control the disease with fewer infusions. The study involves 40 adults aged 18-60 and will track immune cells, nerve damage markers, and relapse rates over 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
College Park Family Care Center Physicians Group
Overland Park, Kansas, 66212, United States
-
UT Southwestern Medical center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.